Tag: Aflibercept

Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial

pallavi123- February 27, 2022

Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase 2b/3 clinical trial in neovascular (wet) age-related ... Read More

DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial

pharmanewsdaily- October 15, 2019

Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer ... Read More

Novartis bags Beovu FDA approval for wet AMD

pharmanewsdaily- October 9, 2019

Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu ... Read More

Regeneron secures updated label approval from FDA for EYLEA in wet-AMD

pharmanewsdaily- August 19, 2018

The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) by Regeneron Pharmaceuticals for EYLEA (aflibercept) Injection in patients with ... Read More